Drug Safety Navigator, LLC

Pharmacy Market

Lilly | November 18, 2020

Seven days after Eli Lilly won a FDA crisis approval for its COVID-19 counter acting agent, worries over restricted supplies are as of now springing up, and the organization is getting an accomplished assembling accomplice to help with the worldwide scale-up. Under a drawn out arrangement with Samsung Biologics, the organizations are set to "incredibly quicken the worldwide gracefully" for Lilly's COVID-19 antibodies, Samsung Biologics said in a delivery. Lilly would...

Pharma Tech

Emerald Health Pharmaceuticals | October 14, 2022

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...

Technology Networks | February 17, 2020

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Business Insights

Direct Biologics | April 13, 2022

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle platform drug technology, announced that the U.S. Food and Drug Administration has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19. The RMAT program is designed to expedite the approval of promising regenerative medical products in the US that demonstrate clin...